SPA
AKBA icon

Sherbrooke Park Advisers’s Akebia Therapeutics AKBA Stock Holding History

Sherbrooke Park Advisers’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-28,387
Closed -$77.5K – 194
2025
Q3 		$77.5K Buy
+28,387
New +$94.4K 0.04% 471

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Sherbrooke Park Advisers's AKBA Position: Q4 2025 in Review

Sherbrooke Park Advisers sold out of Akebia Therapeutics (AKBA) in Q4 2025, closing a stake of 28,387 shares — an estimated $77.5K sold.

Sherbrooke Park Advisers first reported a position in AKBA in Q3 2025 and held it in 1 quarter. The position peaked at $77.5K in Q3 2025. 165 funds tracked by Wall St. Rank hold AKBA as of Q4 2025.

  • Sherbrooke Park Advisers reported no remaining Akebia Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 28,387 Akebia Therapeutics shares in Q4 2025, an estimated $77.5K.
  • Sherbrooke Park Advisers first reported a position in Akebia Therapeutics in Q3 2025 and held it in 1 quarter.
  • Sherbrooke Park Advisers's Akebia Therapeutics position peaked at $77.5K in Q3 2025.
  • 165 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.